New York, New York–(Newsfile Corp. – December 31, 2024) – Leading securities law firm Bleichmar Fonti & Auld LLP announced an investigation into BioAge Labs, Inc. (NASDAQ: BIOA) for potential violations of federal securities laws.

If you are investing in BioAge, you are encouraged to get more information by visiting https://www.bfalaw.com/cases-investigations/bioage-labs-inc.

Why is BioAge Under Investigation?

BioAge Labs, Inc. is a clinical stage biopharmaceutical company specializing in the development of therapeutic products for metabolic diseases, with a primary focus on obesity. The company’s lead product candidate, azelaprag, is a functional small molecule apelin receptor (APJ) agonist, designed to promote weight loss.

During the relevant period, the company said that azelaprag was well tolerated by 265 individuals in eight Phase 1 clinical trials and that after the company’s IPO it is “well equipped to advance our clinical program (.)”

The Stock Drops as the Truth Is Revealed

On December 6, 2024, BioAge announced that it was stopping the STRIDES Phase 2 trial for azelaprag, due to safety concerns, after liver transaminitis was observed in subjects receiving azelaprag. The company said the decision to stop the STRIDES Phase 2 study of azelaprag “was made clear” due to “the emerging safety profile of the current doses tested (.)”

This news caused the company’s stock price to drop by 76%, from a closing price of $20.09 per share on December 6, 2024, to $4.65 per share on December 9, 2024.

Click here for more information: https://www.bfalaw.com/cases-investigations/bioage-labs-inc.

What Can You Do?

If you invest in BioAge you may have legal options and are encouraged to submit your information to the company.

All representation is on a contingency fee basis, at no cost to you. Shareholders are not responsible for any court costs or litigation costs. The company will seek court approval for any potential fees and costs.

Submit your information by visiting:

https://www.bfalaw.com/cases-investigations/bioage-labs-inc

Why Bleichmar Fonti & Auld LLP?

Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys were named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable achievements, BFA has recovered over $900 million in equity from Tesla (NASDAQ: ), Inc.’s Board of Directors (pending court approval), as well as $420 million from Teva Pharmaceuticals (NYSE:) Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases-investigations/bioage-labs-inc

Lawyer advertising. Past results do not guarantee future results.

To view the original version of this press release, please visit https://www.newsfilecorp.com/release/234493